热门资讯> 正文
Inovio在股票发行定价后下跌
2024-04-16 19:48
- Inovio Pharmaceuticals (NASDAQ:INO) lost ~21% premarket Tuesday after the DNA medicine developer priced an underwritten offering of its common stock below its currently traded price.
- Plymouth Meeting, a Pennsylvania-based biotech, intends to raise ~36M in gross proceeds from the offering, which includes pre-funded warrants. The projection excludes underwriting discounts and commissions and estimated offering expenses.
- Inovio (INO) said that the stock issuance allows investors to buy more than 2.5M shares of the company’s common stock at a $7.693 per-share price.
- With pre-funded warrants, investors can purchase over 2.1M shares of common stock at $7.692 per pre-funded warrant.
- The offering led by Deep Track Capital is expected to close on or about April 18. Oppenheimer & Co. and Citizens JMP serve as its joint book-running managers.
More on Inovio Pharmaceuticals
- Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call Transcript
- Inovio Pharmaceuticals, Inc. (INO) CEO Jacque Shea Presents at Oppenheimer 34th Annual Healthcare Life Sciences Conference Transcript
- Inovio: Planning A BLA To Reverse Its Long Path Of Misfortunes
- Inovio Pharmaceuticals GAAP EPS of -$1.10 beats by $0.14, revenue of $103k
- Inovio Pharmaceuticals Q4 2023 Earnings Preview
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
